Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
Acrivon Therapeutics, a clinical-stage biopharmaceutical company specializing in precision oncology, will present at the Jefferies Global Healthcare Conference on June 5, 2024. The company's CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat at 9:30 a.m. ET. The event will be webcast live and accessible via the company's investor relations page. The presentation will utilize Acrivon's proprietary AP3 platform, which identifies patients whose tumors are likely to respond to specific oncology treatments. A replay of the webcast will be available for 30 days.
- Acrivon's presentation at a prominent healthcare conference enhances visibility and potential investor interest.
- Participation by the CEO underscores the company's commitment and leadership.
- The focus on the AP3 platform highlights innovative technology in the precision oncology space.
- The announcement lacks significant new data or clinical results, which may disappoint investors seeking substantial updates.
- Potential over-reliance on proprietary technology (AP3) without showcasing broader clinical success.
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Wednesday, June 5, 2024 at 9:30 a.m. ET at the Jefferies Global Healthcare Conference in New York.
To access the live webcast, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations. A replay of the webcast will be available via the same link for 30 days following the event.
About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner. These distinctive capabilities enable AP3’s direct application for drug design optimization for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates. Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. Acrivon’s ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from past third-party Phase 2 trials in patients with ovarian cancer treated with ACR-368. The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of ovarian cancer patients who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary AP3 precision medicine platform for developing its co-crystallography-driven, internally-discovered preclinical stage pipeline programs. These include ACR-2316, a potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity as demonstrated in preclinical studies against benchmark inhibitors, and a cell cycle program with an undisclosed target.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law.
Investor and Media Contacts:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com
Alexandra Santos
asantos@wheelhouselsa.com
FAQ
When will Acrivon Therapeutics present at the Jefferies Global Healthcare Conference?
How can I view Acrivon Therapeutics' presentation at the Jefferies Global Healthcare Conference?
What is the focus of Acrivon Therapeutics' presentation at the Jefferies Global Healthcare Conference?
Who will represent Acrivon Therapeutics at the Jefferies Global Healthcare Conference?
What is the significance of Acrivon Therapeutics' AP3 platform?
